Equities
  • Price (EUR)351.20
  • Today's Change-0.10 / -0.03%
  • Shares traded0.00
  • 1 Year change+32.60%
  • Beta--
Data delayed at least 15 minutes, as of Oct 22 2021 07:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions. The Company operates through segments such as Core Illumina. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina consists of its core operations. The Company's portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

  • Revenue in USD (TTM)3.97bn
  • Net income in USD768.00m
  • Incorporated2000
  • Employees7.80k
  • Location
    Illumina Inc5200 Illumina WaySAN DIEGO 92122-4616United StatesUSA
  • Phone+1 (858) 202-4500
  • Fax+1 (858) 202-4766
  • Websitehttps://www.illumina.com
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.